This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n4http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F12%3A33148889%21RIV14-MSM-15110___/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n15http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F12%3A33148889%21RIV14-MSM-15110___
rdf:type
n15:Vysledek skos:Concept
dcterms:description
Aims We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. Methods and results: SHIFT was a double-blind clinical trial in which 6505 patients with moderate-to-severe HF and left ventricular systolic dysfunction, all of whom had been hospitalized for HF during the preceding year, were randomized to ivabradine or to placebo on a background of guideline-recommended HF therapy (including maximized b-blockade). In total, 1186 patients experienced at least one additional HF hospitalization during the study, 472 suffered at least two, and 218 suffered at least 3. Patients with additional HF hospitalizations had more severe disease than those without. Ivabradine was associated with fewer total HF hospitalizations [902 vs. 1211 events with placebo; incidence rate ratio, 0.75, 95% confidence interval (CI), 0.65-0.87, P Ľ 0.0002] during the 22.9-month median follow-up. Ivabradine-treated patients evidenced lower risk for a second or third additional HF hospitalization [hazard ratio (HR): 0.66, 95% CI, 0.55-0.79, P , 0.001 and HR: 0.71, 95% CI, 0.54-0.93, P Ľ 0.012, respectively]. Similar observations were made for all-cause and cardiovascular hospitalizations. Conclusion: Treatment with ivabradine, on a background of guidelines-based HF therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening HF. This benefit can be expected to improve the quality of life and to substantially reduce health-care costs. Aims We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. Methods and results: SHIFT was a double-blind clinical trial in which 6505 patients with moderate-to-severe HF and left ventricular systolic dysfunction, all of whom had been hospitalized for HF during the preceding year, were randomized to ivabradine or to placebo on a background of guideline-recommended HF therapy (including maximized b-blockade). In total, 1186 patients experienced at least one additional HF hospitalization during the study, 472 suffered at least two, and 218 suffered at least 3. Patients with additional HF hospitalizations had more severe disease than those without. Ivabradine was associated with fewer total HF hospitalizations [902 vs. 1211 events with placebo; incidence rate ratio, 0.75, 95% confidence interval (CI), 0.65-0.87, P Ľ 0.0002] during the 22.9-month median follow-up. Ivabradine-treated patients evidenced lower risk for a second or third additional HF hospitalization [hazard ratio (HR): 0.66, 95% CI, 0.55-0.79, P , 0.001 and HR: 0.71, 95% CI, 0.54-0.93, P Ľ 0.012, respectively]. Similar observations were made for all-cause and cardiovascular hospitalizations. Conclusion: Treatment with ivabradine, on a background of guidelines-based HF therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening HF. This benefit can be expected to improve the quality of life and to substantially reduce health-care costs.
dcterms:title
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
skos:prefLabel
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
skos:notation
RIV/61989592:15110/12:33148889!RIV14-MSM-15110___
n15:predkladatel
n17:orjk%3A15110
n3:aktivita
n12:N
n3:aktivity
N
n3:cisloPeriodika
22
n3:dodaniDat
n5:2014
n3:domaciTvurceVysledku
n11:6864791
n3:druhVysledku
n16:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n4:predkladatel
n3:idSjednocenehoVysledku
133110
n3:idVysledku
RIV/61989592:15110/12:33148889
n3:jazykVysledku
n7:eng
n3:klicovaSlova
Heart rate; Left ventricular systolic dysfunction; Ivabradine; Hospitalization; Heart failure
n3:klicoveSlovo
n8:Heart%20failure n8:Left%20ventricular%20systolic%20dysfunction n8:Ivabradine n8:Heart%20rate n8:Hospitalization
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[AD70C3144DFD]
n3:nazevZdroje
European Heart Journal (print)
n3:obor
n13:FA
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
793
n3:rokUplatneniVysledku
n5:2012
n3:svazekPeriodika
33
n3:tvurceVysledku
Borer, Jeffrey S Galuszka, Jan Ford, Ian Böhm, Michael
s:issn
0195-668X
s:numberOfPages
8
n14:doi
10.1093/eurheartj/ehs259
n19:organizacniJednotka
15110